Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · November 05, 2022

Esomeprazole vs Vonoprazan for GERD in Patients With a Partial Response to a Proton-Pump Inhibitor

Neurogastroenterology and Motility


Additional Info

Disclosure statements are available on the authors' profiles:

Neurogastroenterology and Motility
Randomized clinical trial: A double-blind, proof-of-concept, phase 2 study evaluating the efficacy and safety of vonoprazan 20 or 40 mg versus esomeprazole 40 mg in patients with symptomatic gastro-esophageal reflux disease and partial response to a healing dose of a proton-pump inhibitor
Neurogastroenterol. Motil. 2022 Sep 30;[EPub Ahead of Print], J Tack, B Vladimirov, I Horny, CF Chong, J Eisner, R Czerniak, Y Takanami

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading